ANAVEX LIFE SCIENCES CORP. AVXL
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS")
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.
treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
Last close
1.33
2026-10-23
Market cap
$123.3M
2026-06-30 share count
52-week range
1.14 - 8.79
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.54
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M | $25.2M | $22.3M | $13.3M | $10.7M | $7.3M |
| SG&A | $13.8M | $11.0M | $12.0M | $13.1M | $9.0M | $5.9M | $6.8M | $6.0M | $5.0M | $8.3M |
| Total operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M | -$31.1M | $29.1M | $19.3M | $15.7M | $15.6M |
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M | -$31.1M | — | — | — | — |
| Interest expense | $4.7M | $7.3M | $6.5M | $947.0K | $26.0K | $180.0K | $207.3K | $255.1K | $88.1K | $11.3K |
| Pre-tax income | -$46.4M | -$43.0M | -$47.5M | -$47.6M | -$37.6M | -$26.3M | -$26.2M | -$17.2M | -$13.4M | -$14.7M |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M | -$26.3M | -$26.3M | -$17.3M | -$13.5M | -$14.7M |
| EPS, basic | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | — | — | — | — | -0.42 |
| EPS, diluted | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 |
| Shares, diluted (wtd. avg.) | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | — | — | — | — | 35.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.2M | $22.2M | $22.9M | $27.4M | $9.2M |
| Total current assets | — | — | — | — | — | — | $25.3M | $26.1M | $27.8M | $9.4M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M | $34.5M | $25.3M | $26.2M | $27.8M | $9.5M |
| Accounts payable | $4.2M | $9.6M | $4.3M | $3.8M | $4.7M | $4.0M | $3.5M | $3.0M | $3.6M | $3.1M |
| Total current liabilities | — | — | — | — | — | — | $5.0M | $3.9M | $3.6M | $3.2M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M | $7.3M | $5.0M | — | $3.6M | $3.2M |
| Retained earnings | -$382.4M | -$336.1M | -$293.1M | -$245.6M | -$197.6M | -$159.7M | -$133.4M | -$107.1M | -$89.8M | -$78.0M |
| Total equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M | $20.3M | $22.3M | $25.9M | $6.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M | -$21.3M | -$18.5M | -$12.6M | -$9.0M | -$9.2M |
| Depreciation and amortisation | — | — | — | — | — | — | — | — | — | $1.3K |
| Stock-based compensation | $11.5M | $9.4M | $16.4M | $18.4M | $8.2M | $4.9M | $6.4M | $5.5M | $4.1M | $5.1M |
| Financing cash flow | $9.4M | $12.0M | $29.7M | $21.3M | $153.2M | $28.4M | $17.8M | $8.1M | $27.3M | $3.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001731122-26-001164.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$14.7M | -$13.5M | -$17.3M | -$26.3M | -$26.3M | -$37.9M | -$48.0M | -$47.5M | -$43.0M | -$46.4M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |